**Therapeutics** for the most common & fatal type of **brain cancer**
- The molecular mechanism of treatment resistance in glioblastoma now revealed as overexpression of PP2A inhibitor PME-1 (Kaur et al., Cancer Res, Epub 2016)
- Efficient therapy is accomplished by combining the blocking of PME-1 and/or HDAC4 with chemotherapy
- Significant evidence in a xenograft mouse model

**Prognostic** gene variants in **aggressive prostate cancer**
- Genetic predisposition to aggressive PrCa in Caucasians now traced to two synergistic germline mutations (ms submitted)
- Dual carriers of the two gene variants have a high risk of developing clinically relevant prostate cancer (OR 23.4) and especially aggressive PrCa such as CRPC (OR 36.6).
- Provides a new tool for patient stratification and for improved personalized care with more informed therapeutic actions
  - WO2017203100A1

**Immunostimulatory** glycocluster **compounds** for **immunotherapy of cancers**
- Used in monotherapy or as adjuvants to stimulate immune response towards malignant cells
- Significantly suppressed the growth of melanoma in a xenograft mouse model
  - WO2012175813A1; WO2017109298A1; WO2017207542A1

**Prognostic expression marker for Acute Myeloid Leukemia (AML)**
- A novel oncogene variant predicting poor survival in AML (HR 1.51)
- Allows stratification of patients with the poorest prognosis for the most efficient therapies
- Allows differentiation of good risk patients among intermediate risk patients
- Independent of current risk grouping – provides significant added value for personalized therapy
- Priority patent application FI20176032 (public 05/2019)

**Novel immuno-oncological** approach
- Efficient elimination of the tumor cell-derived immunosuppressant adenosine
- Invention directly combinable with therapeutic antibodies (e.g. anti-CD73 / anti-CD39)
- Targets aggressive cancers such as melanoma
- Efficacy studies in mouse cancer models (ongoing)
- Priority patent application public 07/2019

---

**CONTACT INFORMATION**
Piia von Lode, PhD
Innovation Manager
piia.vonlode@utu.fi

University of Turku
Innovation Services / UTU TTO
FI-20014 TURUN YLIOPISTO

utu.fi/tto